Study of Serum Hepcidine Levels in Beta Thalassemia Major Patients
Authors/Creators
- 1. Senior Resident, Department of Biochemistry, MGM Medical College and Super Speciality Hospital Indore, MP
- 2. Senior Resident, Department of Pathology MGM Medical College, Indore
- 3. Senior Resident, Department of Pathology, MGMMC, Indore
- 4. Associated Professor, Forensic Medicine, MGM Medical College, Indore
- 5. HOD, Department of Biochemistry, MGM Medical College, Indore
- 6. Assistant Professor, Department of Biochemistry, MGMMC, Indore
Description
Introduction: Thalassemia is a group of hereditary single gene disorders of haemoglobin chains. Excess iron in vital organs is known to cause impaired organ function and increased rates of morbidity and mortality. The regulation of iron by hepcidin is of clinical importance in thalassemia patients, as anemia often occurs along with iron overload. Our aim was to determine serum hepcidin level in beta thalassemia patients and healthy controls and to compare serum hepcidin level in beta thalassemia major patients and healthy controls. Material & Methods: This was a case–control study. Total 35 diagnosed patients of β-thalassemia major were taken as cases, and 35 healthy, age and sex matched individuals were included as controls after taking informed consent. Samples were taken for determination of serum Hepcidin levels along with serum iron, serum ferritin and total iron binding capacity. Observation and Results: 35 beta thalassemia major patients and 35 age and sex matched healthy controls were included in the study. Both groups comprised of 21 boys and 14 girls. Serum hepcidin level was found significantly low in Thalassemia patients as compared to the controls. Discussion: Iron overload in β‑thalassemia patients is a major cause of mortality and morbidity leading to a marked cellular damage and organ dysfunction. The increase in serum ferritin in β‑thalassemia patients is mainly due to the suppression of hepcidin caused by ineffective erythropoiesis which then increases iron absorption. Conclusion: Determination of hepcidin concentration is a useful indicator for high risk of iron toxicity in patients of beta thalassemia.
Abstract (English)
Introduction: Thalassemia is a group of hereditary single gene disorders of haemoglobin chains. Excess iron in vital organs is known to cause impaired organ function and increased rates of morbidity and mortality. The regulation of iron by hepcidin is of clinical importance in thalassemia patients, as anemia often occurs along with iron overload. Our aim was to determine serum hepcidin level in beta thalassemia patients and healthy controls and to compare serum hepcidin level in beta thalassemia major patients and healthy controls. Material & Methods: This was a case–control study. Total 35 diagnosed patients of β-thalassemia major were taken as cases, and 35 healthy, age and sex matched individuals were included as controls after taking informed consent. Samples were taken for determination of serum Hepcidin levels along with serum iron, serum ferritin and total iron binding capacity. Observation and Results: 35 beta thalassemia major patients and 35 age and sex matched healthy controls were included in the study. Both groups comprised of 21 boys and 14 girls. Serum hepcidin level was found significantly low in Thalassemia patients as compared to the controls. Discussion: Iron overload in β‑thalassemia patients is a major cause of mortality and morbidity leading to a marked cellular damage and organ dysfunction. The increase in serum ferritin in β‑thalassemia patients is mainly due to the suppression of hepcidin caused by ineffective erythropoiesis which then increases iron absorption. Conclusion: Determination of hepcidin concentration is a useful indicator for high risk of iron toxicity in patients of beta thalassemia.
Files
IJTPR,Vol14,Issue5,Article25.pdf
Files
(320.8 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:c3c6319c693d3c5f7c49c58fdd4e2d81
|
320.8 kB | Preview Download |
Additional details
Dates
- Accepted
-
2024-04-26
Software
References
- 1. Clark RJ, Tan CC, Preza GC, Nemeth E, Ganz T and Craik DJ: Understanding the structure/activity relationships of the iron regulatory peptide hepcidin. Chem Biol. 2011; 18: 336-343. 2. Haiyuni MY, Aziee S, Nasir A, Abdullah WZ and Johan MF: LARP2 DNA methylation in transfusion-dependent haemo- globin E-beta (HBE/β) and β-thalassaemia major patients. Mal J Med Health Sci. 2019; 15: 46-53. 3. Mackenzie EL, Iwasaki K and Tsuji Y: Intracellular iron transport and storage: From molecular mechanisms to health implications. Antioxid Redox Signal. 2008; 10: 997-1030. 4. Gardenghi, S., Ramos, P., Marongiu, M.F., Melchiori, L., Breda, L., Guy, E. et al. (2010) Hepcidin as a therapeutic tool to limit iron overload and improve anemia in betathalassemic mice. J. Clin. Invest. 2010; 120: 4466–4477. https://doi.org/10.1172/JCI41717 5. Nemeth, E. Hepcidin in beta-thalassemia. Ann. N.Y. Acad. Sci. 2010;1202: 31–35. https://doi.org/10.1111/j.1749- 6632.2010.05585.x 6. Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, Vaulont S. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A. 2001 Jul 17; 98(15):8780-5. 7. Latour C, Wlodarczyk MF, Jung G, Gineste A, Blanchard N, Ganz T, Roth MP, Coppin H, Kautz L. Erythroferrone contributes to hepcidin repression in a mouse model of malarial anemia. Haematologica. 2017 Jan; 102(1):60-68. 8. Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, Sirito M, Sawadogo M, Kahn A, Vaulont S. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci U S A. 2002 Apr 02; 99(7):4596-601. 9. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol. 2009; 122(2- 3):78-86. 10. Nicolas G, Viatte L, Lou DQ, Bennoun M, Beaumont C, Kahn A, Andrews NC, Vaulont S. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet. 2003 May;34(1): 97-101. 11. De Sanctis V, Soliman A and Yassin M: Iron overload and glucose metabolism in subjects with β-thalassaemia major: An overview. Curr Diabetes Rev 9: 332-341, 2013. 12. Rund D and Rachmilewitz E: Beta- Thalassemia. N Engl J Med. 2005; 353: 1135-1146. 13. Handa P, Morgan-Stevenson V, Maliken BD, Nelson JE, Washington S, Westerman M, Yeh MM and Kowdley KV: Iron overload results in hepatic oxidative stress, immune cell activation, and hepatocellular ballooning injury, leading to nonalcoholic steatohepatitis in genetically obese mice. Am J Physiol Gastrointest Liver Physiol. 2016; 310: G117-G127. 14. Hassan Al-K, Azemin W-A, Dharmaraj S and Mohd K: Cytotoxic effect of hepcidin (th1-5) on human breast cancer cell line (mcf7). Jurnal Teknologi. 2015; 77(3). doi:10.11113/ jt.v77. 6009. Accessed May 11, 2021. 15. Papanikolaou, G., Tzilianos, M., Christakis, J.I., Bogdanos, D., Tsimirika, K., MacFarlane, J. et al. Hepcidin in iron overload disorders. Blood. 2005; 105: 4103–4105. https://doi.org/10.1182/blood-2004-12-4844 16. Gardenghi, S., Ramos, P., Follenzi, A., Rao, N., Rachmilewitz, E.A., Giardina, P.J. et al. Hepcidin and Hfe in iron overload in betathalassemia. Ann. N.Y. Acad. Sci. 2010; 1202: 221–225. https://doi.org/10.1111/j.1749- 6632.2010.05595.x 17. Gardenghi, S., Ramos, P., Marongiu, M.F., Melchiori, L., Breda, L., Guy, E. et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in betathalassemic mice. J. Clin. Invest. 2010; 120: 4466–4477, https://doi.org/10.1172/JCI41717 18. Haghpanah, S., Esmaeilzadeh, M., Honar, N., Hassani, F., Dehbozorgian, J., Rezaei, N. et al. Relationship between serum hepcidin and ferritin levels in patients with thalassemia major and intermedia in Southern Iran. Iran Red Crescent Med. J. 2015;17: e28343, https:// doi.org/10.5812/ircmj.17 (5)2015.28343.